Why iBio, Inc.’s (IBIO) Stock Is Down 5.52%
As of Tuesday, July 28, iBio, Inc.’s IBIO share price has dipped by 5.52%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company’s technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2–expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Commentary & Analysis
Why iBio, Inc.’s (IBIO) Stock Is Down 6.29%
As of Thursday, July 16, iBio, Inc.’s IBIO share price has dipped by 6.29%, which has investors questioning if this is right time to buy.Michael Rose
Why iBio, Inc.’s (IBIO) Stock Is Down 5.66%
As of Wednesday, July 08, iBio, Inc.’s IBIO share price has dipped by 5.66%, which has investors questioning if this is right time to buy.Jenna Brashear
Why iBio, Inc.’s (IBIO) Stock Is Up 10.57%
As of Wednesday, July 01, iBio, Inc.’s IBIO share price has surged by 10.57%, which has investors questioning if this is right time to sell.Michael Rose
Why iBio, Inc.’s (IBIO) Stock Is Up 5.69%
As of Monday, June 29, iBio, Inc.’s IBIO share price has surged by 5.69%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | IBIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $84.2 | $288.9 | 20% |
|
| Shares Out (Mil) | 145.4 | 54.0 | 70% |
|
| Institutional Ownership | 96.3% | 93.1% | 69% |
|
| Float (Mil) | 34.9 | 41.4 | 39% |
|
| Beta | 1.29 | 0.94 | 75% |
|
| Avg Daily Volume (000s) | 826 | 480 | 68% |
|
| Price Change (52-week) |
61.5% | 59.9% | 84% |
|
| Growth | IBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (47.0%) | 14.1% | 0% |
|
| Net Income (5yr) | (7.3%) | (10.1%) | 31% |
|
| EPS (5yr) | 64.9% | 15.9% | 97 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (61.9%) | (15.6%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 7 | 4 | |
| Current EPS | ($0.080) | ($0.321) | ($0.458) | |
| Month Ago EPS | ($0.078) | ($0.310) | ($0.555) | |
| # Rev Up | na | 0 | 0 | |
| # Rev Down | na | 1 | 1 | |
| Three Months Ago EPS | ($0.077) | ($0.316) | ($0.545) | |
| Year/Year Chg | 9.6% | 0.9% | 94.0% | |
| Financials | IBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $37 | 0% |
|
| Net Income (TTM) (Mil) | ($33) | ($43) | 20% |
|
| EPS (TTM) | ($0.318) | ($1.500) | 31% |
|
| Operating Cash Flow (TTM) (Mil) | ($23) | ($31) | 14% |
|
| Net Cash Flow (TTM) (Mil) | $48 | $2 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 19% |
|
| Enterprise Value (Q1) (Mil) | ($23) | $190 | 1% |
|
| Valuation | IBIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.85 | 2.84 | 16% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | IBIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.9% | 96% |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (54.0%) | (47.7%) | 11% |
|
| ROE | (65.7%) | (55.0%) | 13% |
|
| Liabilities to Assets | 13.5% | 29.6% | 8% |
|
| F-Score | 3 | 3 | 18% |
|
iBio, Inc. did not pass any screens on 9/2/2026.
